Restatement (Unaudited) - Condensed Cash Flow Statement (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2021	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income (loss)	$ (27,561)	$ (5,517)	$ 4,576	$ (941)	$ (28,502)	$ (50,403)	$ 59,073	$ 39,745
Provision for (recovery of) bad debts			(535)	(551)	(574)	(467)	595	(3,986)
Deferred tax (benefit) expense			(109)	(538)	(7,036)	(10,102)	(2,739)	22,322
Depreciation and amortization			6,481	12,964	19,454	25,946	27,474	27,316
Amortization of debt discount and issuance costs			3,586	5,118	13,653	15,036	3,366	3,968
Interest paid-in-kind			0	0	0	0	3,421	2,832
Equity-based compensation			7,911	9,467	11,706	13,757	4,809	799
Contingent consideration	936	(13)	148	135	1,071	2,696	26,441	640
Warranty provision			302	425	305	516	953	1,387
Provision for inventory obsolescence				1,236	654	990	1,225	1,742
Accounts receivable			(5,000)	(30,393)	(50,840)	(116,848)	(23,038)	(40,708)
Inventories			(6,246)	(20,443)	(55,321)	(88,184)	28,340	(94,594)
Income tax receivables			13,003	9,236	9,676	8,106	(16,530)	9,941
Prepaid expenses and other			(3,216)	826	(5,770)	(21,226)	1,101	2,228
Accounts payable			(10,556)	(1,378)	1,948	8,637	(50,519)	105,481
Accounts payable - related party			0	(1,622)	(1,622)	(1,622)	0	0
Accrued expenses and other			5,134	(10,541)	1,683	9,133	10,913	(1,978)
Income tax payable			2,067	(8,814)	(8,185)	(8,754)	6,870	1,944
Lease liabilities			247	68	337	221	0	0
Deferred revenue			(59,941)	(98,363)	(68,474)	(50,619)	(178,960)	306,994
Net cash provided by (used in) operating activities			(42,148)	(134,109)	(165,837)	(263,187)	(122,205)	386,073
Purchase of property, plant and equipment			(570)	(1,200)	(2,252)	(3,357)	(1,338)	(1,697)
Investment in equity security			(10,000)	(11,975)	(11,975)	(11,975)	0	0
Net cash used in investing activities			(10,570)	(13,175)	(14,227)	(15,332)	(1,338)	(1,697)
Proceeds from revolving credit facility				102,000	102,000	126,033	0	0
Principal payments on term loan facility			(30,000)	(31,075)	(132,150)	(133,225)	(115,000)	0
Proceeds from Series A issuance					224,987	224,987	0	0
Proceeds from common stock issuance					120,645	120,645	0	0
Series A equity issuance costs					(7,195)	(7,195)	0	0
Common stock issuance costs					(3,873)	(3,873)	0	0
Payments on revolving credit facility					(102,000)	(126,033)	0	0
Payments on related party loans				0	0	0	(45,558)	0
Contingent consideration				(7,810)	(7,810)	(7,810)	0	0
Deferred offering costs					0	0	(6,464)	0
Debt issuance costs			(6,590)	(6,590)	(6,590)	(6,590)	(36,011)	0
Net cash provided by (used in) financing activities			(36,590)	56,525	188,014	537,748	(129,273)	(63,945)
Net change in cash and cash equivalents			(89,308)	(90,759)	7,950	259,229	(252,816)	320,431
Cash and cash equivalents, beginning of period	17,682	19,133	108,441	108,441	108,441	108,441	361,257	40,826
Cash and cash equivalents, end of period	116,391	17,682	19,133	17,682	116,391	367,670	108,441	$ 361,257
Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income (loss)	(25,552)	(17)	2,887	2,870	(22,682)
Provision for (recovery of) bad debts			(535)	(551)	(574)
Deferred tax (benefit) expense			(71)	1,358	(6,531)
Depreciation and amortization			6,481	12,964	19,454
Amortization of debt discount and issuance costs			3,586	5,118	13,653
Interest paid-in-kind			0	0	0
Equity-based compensation			7,911	9,467	11,706
Contingent consideration	936	(13)	148	135	1,071
Warranty provision			302	425	305
Provision for inventory obsolescence				1,236	654
Accounts receivable			(2,692)	(34,365)	(58,194)
Inventories			(6,246)	(20,443)	(55,321)
Income tax receivables			13,003	7,501	10,705
Prepaid expenses and other			(3,216)	826	(5,770)
Accounts payable			(10,556)	(1,378)	1,948
Accounts payable - related party			0	(1,622)	(1,622)
Accrued expenses and other			5,134	(10,541)	1,683
Income tax payable			1,410	(8,814)	(8,185)
Lease liabilities			247	68	337
Deferred revenue			(59,941)	(98,363)	(68,474)
Net cash provided by (used in) operating activities			(42,148)	(134,109)	(165,837)
Purchase of property, plant and equipment			(570)	(1,200)	(2,252)
Investment in equity security			(10,000)	(11,975)	(11,975)
Net cash used in investing activities			(10,570)	(13,175)	(14,227)
Proceeds from revolving credit facility			0	102,000	102,000
Principal payments on term loan facility			(30,000)	(31,075)	(132,150)
Proceeds from Series A issuance					224,987
Proceeds from common stock issuance					120,645
Series A equity issuance costs					(7,195)
Common stock issuance costs					(3,873)
Payments on revolving credit facility					(102,000)
Payments on related party loans				0	0
Contingent consideration				(7,810)	(7,810)
Deferred offering costs					0
Debt issuance costs			(6,590)	(6,590)	(6,590)
Net cash provided by (used in) financing activities			(36,590)	56,525	188,014
Net change in cash and cash equivalents			(89,308)	(90,759)	7,950
Cash and cash equivalents, beginning of period	17,682	19,133	108,441	108,441	108,441	108,441
Cash and cash equivalents, end of period	116,391	17,682	19,133	17,682	116,391		108,441
Revision of Prior Period, Error Correction, Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income (loss)	(2,009)	(5,500)	1,689	(3,811)	(5,820)
Provision for (recovery of) bad debts
Deferred tax (benefit) expense			(38)	(1,896)	(505)
Depreciation and amortization
Amortization of debt discount and issuance costs
Interest paid-in-kind
Equity-based compensation
Contingent consideration
Warranty provision
Provision for inventory obsolescence
Accounts receivable			(2,308)	3,972	7,354
Inventories
Income tax receivables				1,735	(1,029)
Prepaid expenses and other
Accounts payable
Accounts payable - related party
Accrued expenses and other
Income tax payable			657
Lease liabilities
Deferred revenue			0	0	0
Net cash provided by (used in) operating activities			0	0	0
Purchase of property, plant and equipment
Investment in equity security				0
Net cash used in investing activities			0	0	0
Proceeds from revolving credit facility
Principal payments on term loan facility
Proceeds from Series A issuance
Proceeds from common stock issuance
Series A equity issuance costs
Common stock issuance costs
Payments on revolving credit facility
Payments on related party loans
Contingent consideration				0
Deferred offering costs
Debt issuance costs				0	0
Net cash provided by (used in) financing activities			0	0	0
Net change in cash and cash equivalents			0	0	0
Cash and cash equivalents, beginning of period	0	0
Cash and cash equivalents, end of period	$ 0	$ 0	$ 0	$ 0	$ 0